Sitagliptin and Acute Pancreatitis: A Systematic Review and Meta-analysis
Hyder Osman Mirghani
Internal Medicine and Endocrine, Medical Department, Faculty of Medicine, University of Tabuk, KSA, Saudi Arabia.
Salem Ahmed S. Shaman S. Shaman *
King Khalid Hospital, Ministry of Health, Tabuk, Saudi Arabia.
Ibrahim Mahmoud Hussain Aljwah
King Salman Armed Forces Hospital, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Background and Objectives: Sitagliptin is a dipepidyl peptidase inhibitor (DPP-4i) with gentle antidiabetic effects with a lower risk of hypoglycemia. The association with acute pancreatitis is controversial. The current meta-analysis aimed to assess the relationship of sitagliptin and acute pancreatitis.
Methods: The literature in PubMed and Google Scholar was searched for relevant articles published in the last ten years up to September 2021. The keywords sitagliptins, DPP-4i, acute pancreatitis were used with the protean AND or OR. Among the 204 articles retrieved, 24 full-texts were assessed for eligibility and only five studies (Three from the USA, one from Asia, and one from Canada) met the inclusion criteria for the systematic review. The author name, year of publication, country, type of study, number of patients, and the duration of the study were reported.
Results: There were five studies. The total number of patients were 729808 with 6459 events. The studies showed no increased rate of acute pancreatitis following sitagliptin use, odd ratio, 0.79, 95% CI, 0.29-2.15, a significant heterogeneity was observer, I2 for heterogeneity=98%, P-value, <001, the P-value for overall effect was 0.65 and the chi-square, 160.15.
Interpretation and Conclusion: Sitagliptin use is not associated with acute pancreatitis.
Keywords: Acute pancreatitis, DPP-4i, sitagliptins